
A research letter published this week has suggested that the FDA initiatives to accelerate drug approvals in the US could …

We’ve finally reached the starter’s block when it comes to precision medicine approaches to prostate cancer, but Dr Matthew Hobbs, …

A Phase 3 trial looking at the use of Kisqali (ribociclib) to treat premenopausal or perimenopausal women with hormone-receptor positive, …

Roche has unveiled new Phase 3 data for its haemophilia A treatment Helimbra (emicizumab) in patients over 12 years of …

Disulfiram has been known as an anti-drinking compound for nearly seven decades. Initially, the compound was used in the vulcanisation …

Bioethics international, a non-profit organisation, has published its second annual index ranking pharma companies by the transparency of data from …

Galectin Therapeutics has seen its share value almost halve after its revealed that GR-MD-02, its experimental treatment for non-alcoholic steatohepatitis …

Novartis and GSK have been taken to court by the Australian Competition and Consumer Commission (ACCC) over allegations of falsely …

In the latest boost to the UK’s life sciences strategy, GSK has committed £40 million to its work identifying new …

Novartis is celebrating the news that its drug Rydapt (midostaurin) has been awarded marketing approval in Canada for the treatment …

Veeva took the opportunity at its European Commercial & Medical Summit to reveal the latest upgrade to its Veeva CRM …

Building on their previous research emerging from Professor Roy Taylor’s work at Newcastle University, a study has found that 45.6% …

Novo Nordisk has lifted the curtain on new data from two of its therapies for diabetes, Xultophy (insulin degludec/liraglutide) and …

Psoriasis is a big pharmaceutical market, it’s the most common autoimmune disease in the US and as many as 7.5 …

New data has revealed that the number of UK patients seeking talking therapies on the NHS is on the rise, …